SomatoKine: Is there a use in treating growth disorders?

Current Opinion in Investigational Drugs

Volumn 6, Issue 4, 2005, Pages 373-377

  Kemp, Stephen F ^a   Thrailkill, Kathryn M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Growth hormone; Growth hormone insensitivity syndrome; Insulin like growth factors; Laron syndrome; Short stature hypoglycemia

Indexed keywords

D DIMER; GROWTH HORMONE; HUMAN GROWTH HORMONE; MECASERMIN RINFABATE; PHOSPHATE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATREM;

ANGIOGENESIS; ANOREXIA; BELL PALSY; BLOOD TOXICITY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FACE MALFORMATION; FACIAL NERVE PARALYSIS; GENE DELETION; GROWTH DISORDER; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HAIR GROWTH; HEADACHE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SENSITIVITY; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; JAW DISEASE; KIDNEY HYPERTROPHY; LARON SYNDROME; LIPOHYPERTROPHY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPILLEDEMA; PHOSPHATE BLOOD LEVEL; PRADER WILLI SYNDROME; RETINA EDEMA; REVIEW; RISK REDUCTION; SEIZURE; SHORT STATURE; SIDE EFFECT; SPLENOMEGALY; TONSIL DISEASE; TURNER SYNDROME;

GROWTH DISORDERS; HUMANS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 17644381925     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab (1958) 18(8):901-903.
2. Salmon WD Jr, Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro J Lab Clin Med (1957) 49(6):825-836.
3. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ: Somatomedin: Proposed designation for sulfation factor. Nature (1972) 235(5333):107.
4. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocrine Rev (1995) 16(1):3-34.
5. Rechler MM: Insulin-like growth factor binding proteins. Vitam Horm (1993) 47:1-114.
6. Baxter RC, Martin JL: Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity labeling. Proc Natl Acad Sci USA (1989) 86(18):6898-6902.
7. Spencer EM (Ed): Modern Concepts of Insulin-like Growth Factors: Proceedings of the Second International Symposium on Insulin-Like Growth Factors/Somatomedins. Elsevier Science, New York, NY, USA (1991).
8. Jorgensen JO, Blum WF, Moller N, Ranke MB, Christiansen JS: Short-term changes in serum insulin-like growth factors (IGF) and IGF-binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. J Clin Endocrinol Metab (1991) 72(3):582-587.
9. Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor-I (IGF-I) is the principle source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Nat Acad Sci USA (1999) 96(12):7088-7092.
10. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D: Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest (2002) 110(6):771-781.
11. Binoux M: GH, IGF's, IGF-binding protein-3 and acid-labile subunit: What is the pecking order? Eur J Endocrinol (1997) 137(6):605-609.
12. Ooi GT, Cohen FJ, Tseng LY, Rechler MM, Boisclair YR: Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liver. Mol Endocrinol (1997) 11(7):997-1007.
13. Laron Z, Lilos P, Klinger B: Growth curves for Laron syndrome. Arch Dis Child (1993) 68(6):768-770.
14. Rosenbloom AL: IGF-I treatment of growth hormone insensitivity. In: IGF in Health and Disease. Rosenfeld RG, Roberts CT (Eds), Humana Press, Totowa, NJ, USA (2000):739-770.
15. Savage MO, Burren CP, Blair JC, Woods KA, Metherell L, Clark AJ, Camacho-Hübner C: Growth hormone insensitivity: Pathophysiology, diagnosis, clinical variation and future perspectives. Horm Res (2001) 55(Suppl 2):32-35.
16. Savage MO, Camacho-Hübner C, Dunger DB: Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res (2004) 14(4):301-308.
17. Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, Savage MO: Growth response to rhIGF-I 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: Relationship to severity of phenotype. Clin Endocrinol (1999) 51 6):787-792.
18. Ranke MB, Wollmann HA, Savage MO: Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS). J Pediatr Endocrinol Metab (1999) 12(Suppl 1):259-266.
19. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P: Insulin-like growth factor I improves height in growth hormone insensitivity. Two year's results. Horm Res (1995) 44(6):253-264.
20. Backeljauw PF, Underwood LE: Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. J Clin Endocrinol Metab (1996) 81(9):3312-3317.
21. Backeljauw PF, Underwood LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study. J Clin Endocrinol Metab (2001) 86(4):1504-1510.
22. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med (1996) 335(18):1363-1367.
23. Camacho-Hübner C, Woods KA, Miraki-Moud F, Hindmarsh PC, Clark AJ, Hansson Y, Johnston A, Baxter RC, Savage MO: Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-gene deletion. J Clin Endocrinol Metab (1999) 84(5):1611-1616.
24. Woods KA, Camacho-Hübner C, Bergman RN Barter D, Clark AJ, Savage MO: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab (2000) 85(4):1407-1411.
25. Root AW, Kemp SF, Rundle AC, Dana K, Attie KM: Effect of long-term recombinant growth hormone therapy in children - the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab (1998) 11(3):403-412.
26. Attie KM, Carlsson LM, Rundle AC, Sherman BM: Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. J Pediatr (1995) 127(2):244-250.
27. Rogol AD, Blethen SL, Sy JP, Veldhuis JD: Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over stimulation testing in predicting the linear growth response to GH therapy? Clin Endocrinol (2003) 58(2):229-237.
28. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG: A randomized double-blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab (1995) 80(4):1393-1398.
29. Norman P: SomatoKine (Insmed). Curr Opin Investig Drugs (2003) 4(4):466-471.
30. Tressel TJ, Tatsuno GP, Spratt K, Sommer A: Purification and characterization of human recombinant insulin-like growth factor binding protein 3 expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun (1991) 178(2):625-633.
31. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J: The combination of insulin-like growth factor I and insulin-like growth factor binding-protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity. J Clin Endocrinol Metab (2000) 85(4):1518-1524.
32. Clemmons D, Moses A, Jacobson W, Rogol A, Allan G: IGFI/IGFBP3 by injection or infusion to type II diabetics increases free IGF-I and reduces insulin requirement. Proceedings of American Endocrine Society Conference (2001) 83:Abs OR 9-4.
33. Moses A, Clemmons D, Sommer A, Rogol A, Jacobson W: Effects of IGF-I/IGF BP3 combination (SomatoKine) on glycemia and insulin requirements in type 2 diabetes mellitus (T2DM). Diabetes (2001) 50(2):Abs 510-P.
34. Insmed Inc: Insmed launches pivotal phase III clinical trial in GHIS. Press Release (2003): June 23.
35. Insmed Inc: Insmed reports update on pivotal clinical trial with SomatoKine: Statistically significant increase in growth rate observed at six months. Press Release (2004): July 20.
36. Grahnén A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, Guevara-Aguirre J, Rosenfeld RG, Sietnieks A: Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl (1993) 82(Suppl 391):9-13.
37. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res (1999) 51(3):128-134.
38. Camacho-Hübner C, Woods KA, Miraki-Moud F, Hindmarsh PC, Clark AJ, Hansson Y, Johnston A, Baxter R, Savage MO: Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J Clin Endocrinol Metab (1999) 84(5):1611-1616.
39. Adams S, Moore J, Chu S, Bagi C, DeLeon L, Liu C, Schmidt D, Sommer A: Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey. Prog Growth Factor Res (1995) 6(2-4): 347-356.
40. Camacho-Hübner C, Storr H, Miraki-Moud F, Rose S, Preece M, Sleevi M, Allan G, Sommer A, Savage MO: Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome. Proceedings of the American Endocrine Society Conference (2003) 85:Abs OR5-48.
41. Rogol AD, Sommer A, Jacobson A, Jacobson W, Smith A, Hernandez R, Allan G: A double-blind, randomized, placebo-controlled study to determine the dose response profile of rhIGF-I/rhIGFBP-3 in subjects with type 2 diabetes mellitus requiring insulin therapy. Diabetes (2002) 51(2):Abs 577-P.
42. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J: Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor. Diabetologia (1993) 36(4):282-291.
43. Chantelau E: Evidence that upregulation of serum IGF-I concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol (1998) 82(7):725-730.
44. Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW: Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1) and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 82(9):2809-2815.
45. Wang Q, Dills DG, Klein R, Klein BE, Moss SE: Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes (1995) 44(2):161-164.
46. Agardh CD, Agardh E, Eckert B, Sjoberg U: Growth hormone levels in the basal state and after thyrotropin-releasing hormone stimulation in young type 1 (insulin-dependent) diabetic patients with severe retinopathy. Diabetes Res (1992) 19(2):81-85.